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SUMMARY
Akt is a central regulator of cell growth. Its activity can be negatively regulated by the phosphatase PHLPP
that specifically dephosphorylates the hydrophobic motif of Akt (Ser473 in Akt1). However, how PHLPP is
targeted to Akt is not clear. Here we show that FKBP51 (FK506-binding protein 51) acts as a scaffolding
protein for Akt and PHLPP and promotes dephosphorylation of Akt. Furthermore, FKBP51 is downregulated
in pancreatic cancer tissue samples and several cancer cell lines. Decreased FKBP51 expression in cancer
cells results in hyperphosphorylation of Akt and decreased cell death following genotoxic stress. Overall, our
findings identify FKBP51 as a negative regulator of the Akt pathway, with potentially important implications
for cancer etiology and response to chemotherapy.INTRODUCTION
The serine/threonine kinase Akt (also called PKB) is a central
module in cell signaling downstream of a variety of stimuli
(Manning and Cantley, 2007). Akt is a major kinase downstream
of phosphatidylinositol 3-kinase (PI3K). PI3K converts phospha-
tidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-
3,4,5-trisphosphate (PIP3), which in turn recruits Akt and PDK1
to the plasma membrane (Brazil and Hemmings, 2001). PDK1
then phosphorylates the activation loop of Akt at Thr308 (Alessi
et al., 1997). Akt is also phosphorylated at Ser473, and the phos-
phorylation of both Ser473 and Thr308 is required for the full acti-
vation of Akt (Alessi et al., 1996) The kinase that phosphorylates
Ser473 remained elusive until mTOR complex 2 (mTORC2) was
found to directly phosphorylate Akt at Ser473 (Sarbassov et al.,
2005). By contrast, the phosphatase PHLPP (PH domain
leucine-rich repeat protein phosphatase) was shown to specifi-
cally dephosphorylate the hydrophobic motif of Akt (Ser473 inCAkt1) and inhibit Akt activity (Brognard et al., 2007; Gao et al.,
2005). However, how Akt is targeted to PHLPP is not clear.
Akt has been shown to inhibit apoptosis and promote cell
survival, activities that contribute to its oncogenic potential
(Manning and Cantley, 2007). Several mechanisms underlie
Akt’s antiapoptotic effect. First, Akt phosphorylates the proa-
poptotic protein BAD, preventing binding to its target protein
(Datta et al., 1997; del Peso et al., 1997). Second, Akt phosphor-
ylates FOXO transcription factors, resulting in their export from
the nucleus and the downregulation of FOXO target genes (Biggs
et al., 1999; Brunet et al., 1999; Kops et al., 1999; Rena et al.,
1999), including the proapoptotic BH3-only protein BIM. Third,
Akt phosphorylates MDM2, resulting in its translocation to the
nucleus, and facilitating MDM2’s inhibition of p53 (Mayo and
Donner, 2001; Zhou et al., 2001). Finally, Akt phosphorylates
and inhibits GSK isoforms (Cross et al., 1995) that play a proa-
poptotic role by inhibiting antiapoptotic protein MCL-1 (Maurer
et al., 2006). Therefore, Akt activity needs to be tightly regulatedSIGNIFICANCE
Resistance to chemotherapy is a major hurdle for successful cancer therapy. Therefore, an improved understanding of the
mechanisms responsible for chemoresistance will be helpful in the development of strategies to sensitize cancer cells to
chemotherapy. We have found that decreased expression of FKBP51 results in resistance to chemotherapy. Mechanisti-
cally, we found that FKBP51 negatively regulates Akt through an apparent scaffolding function. Our studies identified
FKBP51 as an important determinant for cancer cell response to chemotherapy and revealed one mechanism by which
cancer cells are resistant to chemotherapy.ancer Cell 16, 259–266, September 8, 2009 ª2009 Elsevier Inc. 259
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predisposition and cancer cell resistance to chemotherapy.
We recently identified FKBP51 (also called FKBP5) as a regu-
lator of cell death in response to gemcitabine (Li et al., 2008);
downregulation of FKBP51 results in decreased cell death in
response to gemcitabine and Ara-C treatment. FKBP51 is
a member of the FK506-binding protein (FKBP) family (Baugh-
man et al., 1995). Like other familymembers, it contains peptidyl-
prolyl cis/trans isomerase (PPIase) activity and FKBP-C domains
(Harding et al., 1989). It is well established that FKBP51 regulates
steroid receptor activation (Cheung and Smith, 2000). In addi-
tion, FKBP51 has been shown to be required for IKK (IkB kinase)
activation (Bouwmeester et al., 2004). However, this action of
FKBP51 on NFkB activation cannot explain the increased
chemoresistance in cells with decreased FKBP51 expression,
because downregulation of FKBP51 should inhibit IKK activation
and lead to increased cellular sensitivity to chemotherapy. This
suggests the existence of other mechanisms by which FKBP51
regulates cell survival.
RESULTS
To examine whether FKBP51 regulates cellular response to
multiple classes of chemotherapeutic drugs, we used microtu-
bule stabilizers and topoisomerase I and II inhibitors to treat
the pancreatic cancer cell line SU86. Downregulation of
FKBP51 with two different siRNAs resulted in increased resis-
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Figure 1. FKBP51 Regulates Cellular
Response to Genotoxic Stress
(A) SU86 cells were transfected with control or
FKBP51 siRNA and then treatedwith the indicated
drugs. Cell survival was determined as described
in Experimental Procedures.
(B) FKBP51+/+ or FKBP51/ cells were treated
with gemcitabine, and cell survival was deter-
mined as in (A).
(C) SU86 cells were transfected with vector or
constructs encoding FLAG-FKBP51. Transfected
cells were treated with gemcitabine, and cell
survival was determined as in (A). Points show
mean values for three independent experiments;
error bars represent standard error of the mean
(SEM).
tance to these treatments (Figures 1A
and S1A available online). Downregula-
tion of FKBP51 also resulted in resis-
tance to these drugs in the lung cancer
cell line A549 and the breast cancer cell
line MDA-MB-231 (Figure S2). Further-
more, loss of FKBP51 expression re-
sulted in increased resistance of mouse
embryonic fibroblasts (MEFs) to gemci-
tabine (Figure 1B). In contrast, overex-
pression of FKBP51 resulted in hyper-
sensitivity to gemcitabine (Figure 1C).
Overall, these results have established
an important role of FKBP51 in regulating
cellular response to a wide range of clin-
ically important antineoplastic agents in both transformed and
nontransformed cells.
This raised the question, how does FKBP51 regulate cellular
response to these therapeutics? We found that overexpression
of FKBP51 resulted in a reduced phosphorylation of Akt at
Ser473, but had no effect on the phosphorylation of Thr308
(Figure 2A). There was no visible difference in Akt phosphoryla-
tion with or without gemcitabine treatment. However, downregu-
lation of FKBP51 resulted in increased Ser473 phosphorylation,
with no effect on Thr308 phosphorylation (Figures 2B and S1A).
Furthermore, hyperphosphorylation of Ser473 was observed in
FKBP51/ MEFs (Figure 2C). These results suggest that
FKBP51 negatively regulates Akt phosphorylation, which might
account for its effects on cell survival.
To further confirm that FKBP51 regulates Akt activity, we
examined the phosphorylation of downstream substrates of
Akt, such as GSK-3b and FOXO1. We found that overexpression
of FKBP51 decreased the phosphorylation of GSK-3b (pSer9
GSK-3b) and FOXO1 (pThr24 FoxO1) (Figure 2A, lower panels),
which was consistent with decreased Akt phosphorylation. In
contrast, downregulation of FKBP51 significantly increased the
phosphorylation of GSK-3b and FOXO1 (Figure 2B, lower
panels). These results confirmed that FKBP51 inhibits Ser473
phosphorylation and Akt activity.
Because FKBP51 specifically regulates Ser473 phosphoryla-
tion, but not Thr308phosphorylation, it is likely that FKBP51 regu-
lates signaling events that directly control Akt phosphorylation260 Cancer Cell 16, 259–266, September 8, 2009 ª2009 Elsevier Inc.
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Figure 2. FKBP51 Regulates Akt Phosphorylation at Ser473 by Promoting Akt-PHLPP Interaction
(A) SU86 cells were transfected for 48 hr with indicated constructs. Cells were treated with dimethyl sulfoxide or gemcitabine (Gem, 20 nM, 12 hr), and the
phosphorylation of Akt, FOXO1, and GSK-3b in cell lysates was detected by western blot.
(B) SU86 cells were transfected with indicated siRNA. Cells were then treated and harvested as in (A).
(C) The phosphorylation of Akt in cell lysates from FKBP51+/+ or FKBP51/ cells was examined.
(D) The coimmunoprecipitation of Akt, PHLPP, and FKBP51 was examined.
(E) 293T cells were transfected with indicated constructs, and the interaction between Akt and PHLPP was examined.
(F) The PHLPP-Akt interaction was examined in FKBP51+/+ and FKBP51/ cells.
(G) Purified recombinant Akt, PHLPP1, and FKBP51 were incubated in vitro as indicated. The Akt-PHLPP interaction was then examined by coimmunoprecipi-
tation.
(H and I) SU86 cells were transfected with FLAG-FKBP51 and/or PHLPP siRNA as indicated. The phosphorylation of Akt and GSK-3b, and sensitivity to
gemcitabine, were then examined. Points show mean values for three independent experiments; error bars represent ± SEM.
(J) SU86 cells were transfected with HA-PHLPP and/or FKBP51 siRNA as indicated. The phosphorylation of Akt and GSK-3b was then examined.Cancer Cell 16, 259–266, September 8, 2009 ª2009 Elsevier Inc. 261
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by mTORC2 and dephosphorylated by PHLPP phosphatases
(PHLPP1 and PHLPP2) (Brognard et al., 2007; Gao et al., 2005;
Sarbassov et al., 2005). Another FKBP family member,
FKBP38, has previously been shown to bind and inhibit mTORC1
activity (Bai et al., 2007). However, we could not detect any inter-
action between FKBP51 and mTOR. Instead, we found that
PHLPP1 and Akt were coimmunoprecipitated with FKBP51
(Figure 2D, upper panels). Similarly, FKBP51 and PHLPP1 were
coimmunoprecipitated with Akt (Figure 2D, lower panels). These
results suggest that FKBP51, Akt, and PHLPP could exist as
a complex in cells.
The findings that FKBP51 interacts with PHLPP and Akt led us
to hypothesize that FKBP51 acts as a scaffolding protein that
promotes the interaction between Akt and PHLPP, thereby
enhancing the dephosphorylation of Akt. To test this hypothesis,
we overexpressed FKBP51 and found that the interaction
between PHLPP and Akt increased in cells with FKBP51 overex-
pression (Figure 2E). Furthermore, there was less interaction
between Akt and PHLPP1 in FKBP51/ cells, than in
FKBP51+/+ cells (Figure 2F). To test whether FKBP51 directly
promotes the Akt-PHLPP interaction, we expressed and affinity
purified FKBP51, PHLPP, and Akt. As shown in Figure 2G,
FKBP51 can increase the interaction between Akt and PHLPP
in vitro.
In the absence of FKBP51, Akt becomes hyperphosphory-
lated at Ser473 due to inefficient binding of PHLPP to Akt, which
might contribute to the chemoresistance observed in cells
depleted of FKBP51. Indeed, cells expressing AktS473D, which
mimics Ser473 phosphorylation, became resistant to gemcita-
bine (Figure S1B). Similarly, depletion of PHLPP rendered cells
resistant to gemcitabine (Figure S1C). These results support
the hypothesis that FKBP51 regulates chemoresistance through
the Akt pathway.
To further confirm that FKBP51 regulates Akt Ser473 phos-
phorylation through PHLPP, we overexpressed FKBP51 while
downregulating PHLPP. As we demonstrated earlier, overex-
pression of FKBP51 alone decreased Akt Ser473 phosphoryla-
tion and downstream GSK-3b phosphorylation. However, these
effects were reversed by reducing PHLPP (Figures 2H and S1D).
Overexpression of FKBP51 did not have further effect on Akt
Ser473 phosphorylation in cells depleted of PHLPP. Consistent
with these observations, although FKBP51 overexpression alone
sensitized cells to gemcitabine treatment, downregulation of
PHLPP reversed this sensitizing effect (Figure 2I). Furthermore,
PHLPP overexpression blocked the effects of FKBP51 knock-
down on Akt Ser473 and GSK-3b phosphorylation (Figure 2J).
These results establish that FKBP51 regulates Akt Ser473 phos-
phorylation through PHLPP.
It is possible that FKBP51 not only increases the Akt-PHLPP
interaction but also enhances the dephosphorylation of Akt by
stimulating PHLPP activity. FKBP51 has peptidylprolyl isom-
erase activity thus could affect PHLPP activity. However, over-
expression of the FKBP51 mutant FD67/68DV, which lacks
peptidylprolyl isomerase activity (Barent et al., 1998), had similar
effect on Akt Ser473 phosphorylation as wild-type (WT) FKBP51
(Figure S3A), suggesting that FKBP51 regulates Akt phosphory-
lation in a peptidylprolyl isomerase-independent manner.
Although it is possible that the binding of FKBP51 to PHLPP262 Cancer Cell 16, 259–266, September 8, 2009 ª2009 Elsevier Indirectly stimulates PHLPP activity, we found that overexpression
or depletion of FKBP51 did not affect PHLPP phosphatase
activity in vitro (Figures S3B and S3C). PHLPP has been shown
to regulate the levels of PKC bII by dephosphorylating the hydro-
phobic motif of PKC bII, resulting in rapid degradation of PKC bII
(Gao et al., 2008). However, FKBP51 did not interact with and did
not significantly affect the phosphorylation or levels of PKC bII,
(Figures S3D and S3E). These results further confirm that
FKBP51 regulates Akt Ser473 phosphorylation mostly through
its scaffolding function.
Akt has three isoforms (Akt1, Akt2, and Akt3) (Manning and
Cantley, 2007). The antibodies that we used in previous experi-
ments recognize all three isoforms. In addition, PHLPP has two
isoforms (PHLPP1 and PHLPP2) (Brognard et al., 2007; Gao
et al., 2005). Previous studies have established that both
PHLPP1 and PHLPP2 dephosphorylate the same hydrophobic
phosphorylation motif on Akts (Ser473 on Akt1), but they inhibit
Akt signaling differently by interacting with distinct Akt isoforms
(Brognard et al., 2007). PHLPP1 specially regulates Akt2 and
Akt3, and PHLPP2 regulates Akt1 and Akt3. We next examined
whether the isoform-specific effects of PHLPP on Akt are regu-
lated by FKBP51. Consistent with previous studies (Brognard
et al., 2007), Akt1 and Akt3 were coimmunoprecipitated with
PHLPP2, whereas Akt2 and Akt3 were coimmunoprecipitated
with PHLPP1 (Figures 3A and 3B). Overexpression of FKBP51
increased the interaction between both PHLPP isoforms with
their corresponding Akt isoforms (Figure 3A), whereas downre-
gulation of FKBP51 decreased these interactions (Figure 3B).
These results suggest that FKBP51 facilitates isoform-specific
interaction between Akt and PHLPP.
To investigate how FKBP51 enhances the Akt-PHLPP interac-
tion, we generated a series of deletion mutants of FKBP51. As
shown in Figure 3C, we found that deletion of either the FKBP1
(residues 1–138) or FKBP2 (138–251) domain abolished the
interaction between FKBP51 and Akt, suggesting that both
domains are required for this interaction. In addition, we found
that the C-terminal TPR domain of FKBP51 was essential for
the binding of FKBP51 to PHLPP. These results suggest that
FKBP51 binds PHLPP and Akt using distinct domains, consis-
tent with our hypothesis that FKBP51 acts as a scaffolding
protein to promote the Akt-PHLPP interaction. If so, we ex-
pected that FKBP51 deletion mutants that could not bind either
Akt or PHLPP would not enhance the Akt-PHLPP interaction.
Indeed, deletion of the FKBP1 domain or the TPR domain abol-
ished the ability of FKBP51 to enhance the Akt-PHLPP interac-
tion (Figure 3D).
To further confirm that the scaffolding function of FKBP51 is
important for the regulation of Akt phosphorylation and cell
survival, we reconstituted FKBP51/ MEFs with wild-type
FKBP51 (FK), FKBP51 deleted of the FKBP1 domain (DN2) or
FKBP51 deleted of the TPR domain (DC2). As shown in Figure 2,
pSer473, pGSK-3b, and pFOXO1 levelswerehigher in FKBP51/
cells than in FKBP51+/+ cells (Figure 3E). Reconstitution of the WT
FKBP51 in FKBP51/ cells returned the phosphorylation levels of
AktSer473, GSK-3b, and FOXO1 to those observed in FKBP51+/+
cells, whereas reconstitutionwith eithermutant had no effect. This
observation correlatedwith a decreased Akt-PHLPP interaction in
the absenceofWTFKBP51 (Figure 3E). Importantly, reconstitution
of WT FKBP51 in FKBP51/ MEFS restored cell sensitivity toc.
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ure 3F), whereas neither mutants had this rescue effect. These
results confirmed that the scaffolding functionof FKBP51 is impor-
tant for the regulation of Akt phosphorylation and cell survival.
Because decrease or loss of FKBP51 expression results in Akt
hyperactivation, which has been observed in many cancers, it is
possible thatFKBP51expression isdownregulated incancercells.
Consistent with this notion, we found that FKBP51 expression is
lost or significantly decreased in a high percentage of the pancre-
atic cancer cell lines and breast cancer cell lines thatweexamined
(Figure 4A). Reconstitution of FKBP51 inMiapaca2 or BxPC3 cells
decreased Akt phosphorylation at Ser473 (Figure 4B), and sensi-
tized these cells to Ara-C (Figure 4C), supporting the hypothesis
that loss of FKBP51 expression renders these cells resistant to
chemotherapy. Furthermore, overexpression of FKBP51 in
a pancreatic cancer cell line (Panc0403) having high endogenous
levels of FKBP51 did not affect Akt phosphorylation (Figure 4B).
C
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A B Figure 3. FKBP51 Scaffolding Function
Regulates Akt Phosphorylation and Cell
Survival
(A) 293T cells or 293T cells stably transfected with
FKBP51 were transfected with AKT isoforms
(lanes 1 and 2, AU1-AKT1; lanes 3 and 4, HA-
AKT2, lane5, 6 HA-AKT3). Cells were lysed, and
lysates were subjected to immunoprecipitation
with indicated antibodies. PHLPP1, PHLPP2,
and AKT in the immunoprecipitates or cell lysates
were detected by immunoblotting.
(B) SU86 cells were transfected with control or
FKBP51 siRNA together with AKT isoforms. The
interaction between Akt isoforms and PHLPP iso-
forms was then examined as in (A).
(C) 293T cells were transfected with different S/
FLAG-tagged FKBP51 truncated mutants.
Lysates from transfected cells were subjected to
immunoprecipitation with S protein agarose,
PHLPP1, and Akt in the immunoprecipitates
were then detected by immunoblotting.
(D) 293T cells were transfected with WT FKBP51
or FKBP51 truncation mutations. Transfected
cells were then lysed, and lysates were subjected
to immunoprecipitation with anti-Akt antibodies.
PHLPP1 and Akt in the immunoprecipitates or
cell lysates were detected by immunoblotting.
(E and F) FKBP51+/+, FKBP51/, or FKBP51/
MEFs stably expressing WT or mutant FKBP51
were used to examine Akt, GSK-3b, and FOXO1
phosphorylation as well as the Akt-PHLPP1 inter-
action (E). Cells were examined for gemcitabine
sensitivity using the MTS assay (F). Points show
mean values for three independent experiments;
error bars represent ± SEM.
These results suggest that cancer cell
lines having high FKBP51 expression
might depend less on the PI3K-Akt
pathway to survive. To test this possibility,
we treated Miapaca2 (low levels of
FKBP51 expression) and Panc0403 (high
levels of FKBP51 expression) with the
PI3K inhibitor wortmannin, together with
gemcitabine. As shown in Figure S4A, Miapaca2 cells are more
sensitive toPI3K inhibition, consistentwith the notion that cells ex-
pressing low levels of FKBP51 might be more dependent on the
PI3K-Akt pathway. However, these two cell lines have different
genetic backgrounds, so factors other than FKBP51 expression
might contribute to their different responses to the PI3K inhibitor.
Our results also imply that FKBP51 might function as a tumor
suppressor. As an initial step to test this hypothesis, we
performed microarray analysis using RNA isolated from 36
pancreatic tumor and 19 normal tissue samples. These were
fresh-frozen samples obtained during surgical procedures. The
microarray data revealed that expression levels of FKBP51
were significantly lower in pancreatic tumor tissue than in normal
pancreatic tissue (Figure 4D). The comparison of expression
profile between normal and tumor tissues identified genes ex-
pressed significantly differently (p < 106) between the two
(Figure S4B). Network analysis using Ingenuity Pathway analysisCancer Cell 16, 259–266, September 8, 2009 ª2009 Elsevier Inc. 263
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a network surrounding Akt was the top network (Figure S4C). We
also performed real-time quantitative reverse-transcriptase poly-
merase chain reaction (QRT-PCR) to validate the microarray
results and found these results to be similar with the correlation
coefficient between the QRT-PCR and microarray data (approx-
imately 0.8, p < 0.0001) (Figure 4E). Furthermore, lower or loss of
FKBP51 protein levels were found in selected pancreatic cancer
samples, many of which had increased Akt/GSK-3b phosphory-
lation (Figures 4F, S4D, andS4E). Decreased expression levels of
FKBP51 were also found in ovarian, head and neck, seminoma,
leukemia, and prostate cancer tissues based on expression
data obtained through the Oncomine (www.oncomine.org).
Overall, our results suggest that FKBP51 negatively regulates
Akt activation through its scaffolding function and that hyperacti-
vation of Akt caused by the loss of FKBP51 might contribute to
tumorigenesis and cancer cell resistance to chemotherapy.
DISCUSSION
Resistance to chemotherapy represents a major challenge for
cancer therapy. Therefore, the identification of biomarkers for
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Figure 4. Loss of FKBP51 Expression in
Cancer Cells and Tissues
(A) Cell lysates from pancreatic and breast cancer
cell lines were blotted with FKBP51 antibodies.
Lysates from normal breast (MCF10A) and
pancreatic (HPDE6-E6E7c7) epithelial cells were
used as controls.
(B and C) Miapaca2, BxPC3, or Panc0403 cells
were reconstituted with FKBP51, and Akt phos-
phorylation and sensitivity to genotoxic stress
were then determined. Points show mean values
for three independent experiments; error bars
represent ± SEM.
(D and E) FKBP51 gene expression in tumor and
normal pancreatic tissues was determined using
microarray analysis (D, 19 normal pancreatic and
36 tumor tissue samples, p = 0.0092) or real-
time quantitative RT-PCR (E, 25 pancreatic cancer
samples and 12 normal pancreatic tissues, p =
0.001). Error bars represent ± SEM.
(F) Western blot of lysates from a subset of tumor
and normal tissues. T, tumor; N, normal pancre-
atic tissue. Numbers 1–8 indicate patient number.
(G) A model illustrates how FKBP51 regulates cell
survival through the Akt pathway.
chemoresistance and understanding
mechanisms of chemoresistance will
reveal possible strategies to overcome
this problem. We have identified FKBP51
as an important determinant of cancer
cell response to a wide range of clinically
important chemotherapeutic agents. De-
creased expression of FKBP51 caused
resistance to chemotherapy in cancer
cell lines. Mechanistically, FKBP51 acts
as a scaffolding protein for Akt and
PHLPP, a phosphatase that specifically
dephosphorylates Akt Ser473 (Gao et al., 2005), thereby
enhancing the phosphatase activity of PHLPP toward Akt.
Because Akt is a major signaling node within the cell, its
activity needs to be tightly regulated. Misregulation of the Akt
pathway can disrupt the balance between cell survival and
death, affecting cancer development and therapy. Indeed, the
PI3K-Akt pathway has been linked to resistance to a variety of
chemotherapeutics, such as gemcitabine, irinotecan, etoposide,
and Taxol (West et al., 2002). Hyperphosphorylation of Akt has
also been linked to poor prognosis in a variety of cancers
(West et al., 2002). Based on our studies, we expect that lower
expression of FKBP51 will also associate with poor prognosis
in clinical settings. This hypothesis remains to be validated in
the future.
Many regulators of the Akt pathway, such as PI3K, PTEN, and
Akt, aremutated in cancers. It is plausible that downregulation or
mutation of FKBP51 contributes to not only chemoresistance but
also tumorigenesis. We found that FKBP51 expression is lost in
many cancer cell lines and pancreatic cancers, supporting a
possible role of FKBP51 in tumor suppression. However, the
causal role of FKBP51 in tumor suppression remains to be deter-
mined.264 Cancer Cell 16, 259–266, September 8, 2009 ª2009 Elsevier Inc.
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FKBP51 Facilitates PHLPP-Akt InteractionOur findings will have a significant impact on the dissection of
components in the pathway controlling Akt activity. Furthermore,
because dysregulation of the Akt pathway is frequently linked to
cancer predisposition and poor prognosis, our findings might
also have important implications for cancer etiology and
response to therapy.
EXPERIMENTAL PROCEDURES
Phosphatase Assay
PHLPP1 was immunoprecipitated with PHLPP1 antibody from the indicated
cells. HA-Akt2 was expressed and purified from 293T cells with hemagglutinin
(HA) tag antibody and subsequent HA peptide elusion. Immunoprecipitated
PHLPP1 was incubated in phosphatase buffer (50 mM Tris [pH 7.4], 1 mM
DTT, and 5 mM MnCl2) with purified phosphorylated Akt at 30
C for 0–
10 min as previously described (Gao et al., 2005).
MTS Assay
AraC, paclitaxel, and docetaxel were purchased fromSigma-Aldrich (St. Louis,
MO) and gemcitabine was provided by Eli Lilly (Indianapolis, IN). Assays with
10-fold diluted concentrations of drugs were performed in triplicate with the
CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega
Corporation, Madison, WI). After incubation with drugs for 72 hr, the plates
were measured in a Safire2 microplate reader (Tecan AG, Switzerland).
Expression Array Data
Total RNAwas extracted from pancreatic tumor tissue samples using QIAGEN
RNeasy Mini kits (QIAGEN Inc. Valencia, CA). These samples were obtained
during clinically indicated surgical procedures and were consented for exper-
imental purposes. The present study was reviewed and approved by Mayo
Clinic Institutional Review Board. RNA quality was tested using an Agilent
2100 Bioanalyzer, followed by hybridization to Affymetrix U133 Plus 2.0 Gen-
eChips (Affymetrix, Inc., Santa Clara, CA). Expression levels were normalized
by GCRMA.
Pancreatic Tissue Sample Preparation for Western Blot
Proteins were extracted from portions of the selected fresh-frozen pancreatic
tumor and normal tissue, samples that were also used to perform microarray
and real time RT-PCR. These samples were consented for research use and
the present study was reviewed and approved by Mayo Clinic Institutional
Review Board. To extract proteins from these tissues, we froze the tissue
samples in liquid nitrogen and cut them into small fragments, followed by incu-
bation on ice in NETN buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM
EDTA, 0.5% Nonidet P-40) containing 50 mM glycerophosphate and 10 mM
NaF, with a protease inhibitor cocktail. The tissues were milled in a blender
for 5 min and lysed on ice for 30 min. The loading buffer for the SDS-PAGE
was added and boiled for 20 min. Samples were then centrifuged before
loading.
Statistical Analysis
Gene signatures between tumor and normal tissues were determined with the
Student’s t test for each probe set. Ingenuity Pathway Analysis was performed
with the most differentially expressed genes (p < 106) between normal and
tumor tissues by calculating the p values for the probability of finding a set
of genes within a given pathway. Fischer’s exact test was used to calculate
the p values.
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